The selective estrogen receptor modulator tamoxifen has been the first targeted drug treatment for more than 50 years for the control of tumor growth via the competitive inhibition of the estrogen receptor (ER) expressed in nearly 80% of breast cancers. This evidence concerns the gene ESR1 and breast carcinoma.